Showing 1621-1630 of 2884 results for "".
- Business News: Dominion Aesthetic Technologies Closes $23.7 Million Series B Financinghttps://modernaesthetics.com/news/business-news-dominion-aesthetic-technologies-closes-237-million-series-b-financing/2473052/Dominion Aesthetic Technologies, developers of EON, closed Series B financing, raising a total of $23.7 million. The series B funding will accelerate the manufacturing and commercialization of EON, an FDA-cleared 1064 nm robotic laser device used for touchless, external non-invasi
- Medspa COVID-19 Safety Procedures: A Checklist Reviewhttps://modernaesthetics.com/news/medspa-covid-19-safety-procedures-a-checklist-review/2473046/COVID-19 is a viral infection that spreads primarily by distribution of droplets from our mouths. When an infected person coughs, sneezes, breathes, drinks, eats, talks, sings, yells, etc., s/he is producing sprays and mists of saliva droplets that carry the virus. When another person inhale
- Allergan Aesthetics Enters Into Option to Acquire Cypris Medicalhttps://modernaesthetics.com/news/allergan-aesthetics-enters-into-option-to-acquire-cypris-medical/2473045/Allergan Aesthetics, an AbbVie company has entered into a warrant agreement with Cypris Medical, a privately held, medical device company based in Chicago. Following the completion of a clinical trial to be initiated in 2021, Allergan Aesthetics will have the right to exercis
- RealSelf Adds One Million Arabic-speaking Monthly Users With Tajmeeli.com Acquisitionhttps://modernaesthetics.com/news/realself-adds-1-million-arabic-speaking-monthly-users-with-tajmeelicom-acquisition/2473043/RealSelf now owns Tajmeeli, the leading cosmetic procedure resource for Arabic speaking consumers. The acquisition adds one million Arabic-speaking monthly active users. "We're excited this acquisition will enable us to expand our reach and resources to over 100 countries
- Melasma Update: Studies Show Benefit with Cysperahttps://modernaesthetics.com/news/melasma-update-studies-show-benefit-with-cyspera/2473042/Several studies recently published in peer reviewed journals demonstrate the safety and efficacy of stabilized-cysteamine 5% cream (Cyspera), the novel, non-hydroquinone, topical pigment regulator from Scientis In a randomized, double-blinded study of 50 melasma patients assigned to eit
- Merz and Candela Announce New Collabhttps://modernaesthetics.com/news/merz-and-candela-announce-new-collab/2473041/Merz Aesthetics and Candela Corporation are joining forces. As part of the collab, sales reprentatives from each company will now have the ability to promote products from both organizations. The companies are not formally changing their structure or formally integr
- Managing Employees During the COVID Pandemic: Answers to Top Questionshttps://modernaesthetics.com/news/managing-employees-in-the-covid-pandemic-answers-to-top-questions/2473040/Can I require staff to get a vaccine in order to continue working? In many cases, vaccines can be required, says Josh Alloy, JD, Counsel at Arnold and Porter in Washington, DC, “although there are potential e
- Revance Therapeutics and Ajinomoto Bio-Pharma Services Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injectionhttps://modernaesthetics.com/news/revance-therapeutics-and-ajinomoto-bio-pharma-services-announce-manufacturing-agreement-for-supply-of-daxibotulinumtoxina-for-injection/2473035/Ajinomoto Bio-Pharma Services will serve as a supply source and provide manufacturing for Revance Therapeutics, Inc.’s DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection is currently under Biologics License Application (BLA) review.
- Revance Update: FDA Defers Approval of DaxibotulinumtoxinA Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspectionhttps://modernaesthetics.com/news/revance-update-fda-defers-approval-of-daxibotulinumtoxina-due-to-covid-19-related-travel-restrictions-impacting-manufacturing-site-inspection/2473027/The U.S. Food and Drug Administration (FDA) deferred a decision on the Biologics License Application (BLA) for Revance’s DaxibotulinumtoxinA for Injection, an investigational neuromodulator product for the treatment of moderate to severe glabellar lines. In a communication r
- Martine Williamson Named Revlon’s New Chief Marketing Officerhttps://modernaesthetics.com/news/martine-williamson-named-revlons-new-chief-marketing-officer/2473025/Martine Williamson is Revlon’s new Chief Marketing Officer. In this role, Williamson will be central to creating and spearheading global strategic plans across the brand portfolio and overseeing Revlon’s overall brand equity and architecture. Williamson officially join